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Statin Therapy for Subclinical Atherosclerosis
in Primary Prevention
Time to Prove It?*
Todd C. Villines, MD
Bethesda, Marylandc
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wCoronary artery calcium (CAC) scanning, as a
measure of coronary artery disease (CAD) burden
(1), has been shown to significantly improve coro-
nary heart disease (CHD) risk prediction in screen-
ing populations when compared with the Framing-
ham Risk Score (2) and high-sensitivity C-reactive
protein testing (3,4). On the basis of the consistent
demonstration of its prognostic value in studies
involving more than 30,000 patients, CAC scan-
ning was recently endorsed by American College
of Cardiology Guidelines as a screening test in
See page 252
patients at intermediate risk (10-year CHD risk:
10% to 20%) (5), and is considered an appropriate
test in low-risk patients (10-year CHD risk:10%)
with a family history of premature CHD (6). The
premise for these recommendations is that screening
for subclinical coronary atherosclerosis and refinement
of individual cardiovascular risk will lead to more
appropriate use of preventative medications, where
patients reclassified to a high-risk strata receive more
intensive preventative therapies proven to reduce car-
diovascular events in secondary prevention cohorts,
whereas patients at very low risk (e.g., Agatston score
of zero) are managed conservatively.
Prospective evaluations of the downstream im-
pact of CAC scanning are limited but suggest that
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iated with increases in statin and aspirin utilization
mong patients with manifest CAC and improve-
ents in cardiovascular risk factors, without in-
reasing costs (7,8). However, remarkably and un-
ortunately, only 1 study has prospectively evaluated
he effect of statin treatment on clinical outcomes in
atients with significantly elevated CAC scores (3).
he St. Francis Heart study (randomized treatment
ortion) was a population-based, randomized,
ouble-blind, placebo-controlled trial that evalu-
ted the effect of atorvastatin 20 mg daily (in
ddition to vitamins C and E) on a combined
ardiovascular endpoint (coronary death, myocar-
ial infarction, coronary revascularization, periph-
ral arterial procedures, and nonhemorrhagic
troke) among approximately 1,000 asymptomatic
ubjects 50 to 70 years of age with significantly
levated Agatston CAC scores, defined as above the
0th percentile for age and gender according to an
nstitutional database (median Agatston score ap-
roximately 370). All subjects were treated with
spirin. The study population is noteworthy because
ersons with Agatston scores 300 have been shown
o be at relatively high CHD risk, with an annualized
vent rate of 2.8% (9). The authors found that active
reatment involving atorvastatin for a median of 4.3
ears did not significantly reduce the primary endpoint
6.9% treated vs. 9.9% placebo; p 0.08); however, in
n unplanned subgroup analysis, subjects with Agat-
ton scores 400 treated with atorvastatin experi-
nced significantly fewer events (8.7% vs. 15.0%; p 
.046). In this trial, lower-than-expected annualized
vent rates in the placebo arm (2% for the combined
ndpoint and1% for hard CHD events) served as a
arning that future trials examining an asymptomatic
creening cohort of similar ages may require increased
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262sample sizes and longer follow-up. Unfortunately,
subsequent trials have not been performed, likely for
cost reasons, and perhaps, as some have suggested, due
to perceived ethical concerns in randomizing subjects
with significantly elevated Agatston scores at increased
CHD risk, to long-term placebo therapy.
In this issue of iJACC, Mulders et al. (10) present
n important post hoc analysis of the St. Francis
eart study assessing whether a family history of
remature CAD influenced the effect of statin
reatment on the combined cardiovascular end-
oint. In a time-to-first event, intention-to-treat
nalysis, among patients with a positive family
istory (n  543), atorvastatin-treated subjects
xperienced significantly fewer cardiovascular
vents as compared with those treated with placebo
7.2% vs. 12.5%; p  0.039). Interestingly, there
as no effect of statin treatment in subjects without
family history of premature CAD (n  462). A
loser look at the results again reveals the relatively
ow event rates in this particular population. This
ay be due to the relatively modest risk factor
urden (mean Framingham Risk Score: 11%), the
se of age- and gender-defined 80th percentile for
nclusion rather than absolute CAC scores (e.g.,
400), a relatively low, static statin dose, the
nknown impact of aspirin use in all subjects, and
ossible unmeasured changes in patient lifestyle
ollowing identification of elevated CAC. Subse-
uently, statistical significance of statin treatment in
atients with a positive family history was only
chieved by the inclusion of “soft” endpoints, such
s coronary revascularization and peripheral arterial
urgery, which accounted for more than one-half of
ll events. Lastly, the percentage of patients with a
ositive family history in this post hoc analysis
54%) was higher than that commonly seen in
rimary prevention populations (typically 35%),
nd higher than reported in the original trial (ap-
roximately 30%) (3). This difference prompted an
udit of the primary study that, reassuringly, con-
rmed the accuracy of the rates of family history in31:126–33. tatin, vitamin C, ancreased rate of family history, an independent risk
actor for hard CHD events, is likely a result of the
tudy design, which included only patients with
ignificantly elevated Agatston scores at a relatively
oung age. It is known that among patients who
ave suffered a premature coronary event, up to 72%
ill have a family history of early CHD (11). This fact
nd the findings of the current study reinforces the
otential of this unique, heterogeneous risk factor to
elect patients for CAD screening using CAC scan-
ing or, as suggested by the authors, statin treatment
n the setting of advanced subclinical coronary athero-
clerosis.
So how are we to manage patients with varying
egrees of subclinical CAD in patients who un-
ergo CAC scanning according to current guide-
ines? Does the presence of family history now
nfluence our decision making? In the absence of
arge-scale outcomes studies, we are left to make an
nformed decision based on the limited, available
ata. Recent meta-analyses have questioned the use
f statins for primary prevention by narrowly focus-
ng on the relatively small absolute reduction in
ll-cause mortality over relatively short treatment
urations, despite clear reductions in hard CHD
vents (coronary death and nonfatal myocardial
nfarction) (12,13). However, within these analyses,
t is clear that the impact of statins is most signif-
cant among patients with increased cardiovascular
isk. Therefore, while we await much-needed large-
cale outcomes trials to better define the role of
edical treatment(s) differentially applied according
o cardiac computed tomography measures of risk, in
atients with advanced subclinical coronary athero-
clerosis, many of us will continue to reach for statins
nd aspirin. If unsure, then perhaps take a good family
istory to help you and your patient decide.
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